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the effect of protease activity on IGFBP-1 immunoreactivity and IGF 
binding was characterised. 125I-IGFBP-1 was incubated with maternal and 
fetal serum, amniotic fluid and placental extracts. Breakdown of 125I-
IGFBP-1 was determined by SDS-PAGE and autoradiography. The size 
distribution of endogenous IGFBP-1 was determined by Western 
immunoblotting. Protease inhibitor studies characterised the proteolytic 
activity and Western ligand blotting with 125I-IGF-I was used to determine 
IGF binding capacity of proteolysed IGFBP-1. Amniotic fluid samples 
collected after labour onset contained proteolytic activity that generated 12 
kDa and 19 kDa IGFBP-1 fragments that did not bind to 125I-IGF-I. This 
activity was not detected in amniotic fluid collected prior to labour onset or 
in other tissues. Activity was blocked by aprotinin, leupeptin, PMSF, and 
Kunitz soybean trypsin inhibitor but not by EDTA or pepstatin. Incubation 
of IGFBP-1 with trypsin generated fragments of a similar size to the 
amniotic fluid protease. In conclusion, we have demonstrated the presence 
in vivo of a trypsin-like proteolytic activity that alters the IGF-binding 
function of IGFBP-1 in pregnancy.  
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Abstract 
The insulin-like growth factors their binding proteins are important for placental and 
fetal growth. In this study we have investigated the presence of proteolytic activity 
directed against IGFBP-1 in pregnancy. In addition, the effect of protease activity on 
IGFBP-1 immunoreactivity and IGF binding was characterised. 125I-IGFBP-1 was 
incubated with maternal and fetal serum, amniotic fluid and placental extracts. 
Breakdown of 125I-IGFBP-1 was determined by SDS-PAGE and autoradiography. 
The size distribution of endogenous IGFBP-1 was determined by Western 
immunoblotting. Protease inhibitor studies characterised the proteolytic activity and 
Western ligand blotting with 125I-IGF-I was used to determine IGF binding capacity of 
proteolysed IGFBP-1. Amniotic fluid samples collected after labour onset contained 
proteolytic activity that generated 12 kDa and 19 kDa IGFBP-1 fragments that did not 
bind to 125I-IGF-I. This activity was not detected in amniotic fluid collected prior to 
labour onset or in other tissues. Activity was blocked by aprotinin, leupeptin, PMSF, 
and Kunitz soybean trypsin inhibitor but not by EDTA or pepstatin. Incubation of 
IGFBP-1 with trypsin generated fragments of a similar size to the amniotic fluid 
protease. In conclusion, we have demonstrated the presence in vivo of a trypsin-like 
proteolytic activity that alters the IGF-binding function of IGFBP-1 in pregnancy.  
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Introduction 
The insulin-like growth factors (IGFs) carry out a range of actions at the cellular level 
in many tissues including the stimulation of cell growth, cell survival and 
differentiation. These actions are regulated by a series of specific binding proteins 
(IGFBPs), which may inhibit or enhance IGF activity [1].   Changes in the production 
of IGFs or IGFBP, as well as differential metabolism, may lead to net changes in the 
effects of the IGF-IGFBP axis on tissue biology. 
 
There is clear evidence that the IGFs and IGFBP family are implicated in the 
regulation of pregnancy. Abnormal production of IGFs and IGFBP-1 are associated 
with disorders of pregnancy such as intrauterine growth restriction and pre-eclampsia 
[2-4]. Indeed, low levels of IGF-I and raised levels of IGFBP-1 are associated with 
placental insufficiency [5]. Throughout pregnancy there is an abundance of IGF 
mRNA, particularly IGF-II mRNA in cytotrophoblast tissue, with the highest gene 
expression found at the invading front of trophoblast columns [6]. IGFBP-1 is the 
major product of the maternal decidua [7]. It is postulated, therefore, that the IGF 
system is involved in placental development and that abnormal expression or levels 
of any component of this system may contribute to disorders of pregnancy.  
 
In addition to changes in production of IGFs or IGFBPs, degradation of IGFBPs can 
decrease their binding to IGFs and hence increase net IGF levels. Proteolysis of 
IGFBP-3 during pregnancy has been studied extensively and proteolytic activity 
directed against IGFBP-2, -4 and –5 have also been described in pregnancy tissues 
[8-13]. These activities result in a decrease in IGF binding capacity and this functional 
modification is therefore thought to allow increased bioavailability of IGFs to tissues and 
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may serve to meet the extra metabolic demands of pregnancy [14].  Similar findings for 
IGFBP-3 have been reported, although most data is from non-pregnancy tissues 
[15].  Evidence for the presence of proteolytic activity directed against IGFBP-1 in 
vivo is equivocal. IGFBP-1 appears to be relatively resistant to proteolysis [8, 14] and 
proteases that cleave other IGFBPs have no effect on IGFBP-1 breakdown [16-19]. 
One group has reported the presence of proteolytic activity directed against 125I-
IGFBP-1 in amniotic fluid and cultured decidual cells, but the extent of proteolysis in 
vivo was not investigated [20].  The decidual activity against IGFBP-1 includes matrix 
metalloproteinases-3, -8 and -9 [21, 22]. However, the impact of this metabolism on 
determination of IGFBP levels is not certain.  
 
The aims of this study were to investigate the metabolism of IGFBP-1 pregnancy 
tissues including amniotic fluid, pregnancy serum and placenta, to characterise the 
enzyme responsible and to investigate the effect of IGFBP-1 breakdown on the 
determination of IGFBP-1 levels by immunoassay. 
 
Materials and Methods 
Tissues 
Samples of maternal serum (n=40), umbilical cord serum (n=40), amniotic fluid 
(n=148), and placenta (n=40) were collected prior to the onset of labour, following 
uncomplicated labour and labour complicated by fetal distress (abnormal 
cardiotocogram) in the presence or absence of meconium staining. Samples of 
placenta (1-2 g wet weight) were suspended in 0.1 M phosphate buffered saline and 
homogenised. The suspension was centrifuged to remove debris and unbroken cells. 
Supernatants were separated and stored at –20 °C until assay. Tissue collection was 
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approved by the Local Ethics Committee and informed consent was obtained from 
each woman.  
 
Methods 
Preparation of 125I IGFBP-1 
IGFBP-1 from amniotic fluid collected between 16 and 20 weeks gestation was 
purified by anion exchange, hydrophobic interaction and gel filtration chromatography 
and iodinated using the chloramine T method [22]. Following iodination, radioactive 
peptides were separated on a Sephadex G-75 size exclusion column eluted with 50 
mM phosphate buffered saline (PBS) containing 1% (w/v) bovine serum albumin.  
 
Proteolysis of 125I-IGFBP-1 
Proteolysis of 125I-IGFBP-1 was investigated using a method similar to that used by 
Lamson et al [24] to investigate 125I-IGFBP-3 proteolysis. Intact 125I-IGFBP-1 (2 µl) 
was added to samples of amniotic fluid, serum or placental extracts (2 µl). Mixtures 
were incubated at 37 °C. SDS-PAGE loading buffer (2 µl) was added to each sample 
and samples were then applied to a discontinuous SDS-PAGE gel and 125I visualised 
by autoradiography.  
 
Preliminary studies were carried out to establish the presence of 125I-IGFBP-1 
breakdown in the different tissues tested. For these experiments, the labelled protein 
was incubated with pregnancy fluids described above (n=8 for each fluid and n=2 for 
each delivery type) for 16h at 37°C. In order to detect intermediate breakdown 
products and determine the incubation time required for 125I-IGFBP-1 proteolysis, 
samples in which proteolytic activity was apparent after 16h incubation were 
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incubated for 0, 5, 10, 20, 30 and 60 minutes with 125I-IGFBP-1 as described above 
prior to SDS-PAGE and autoradiography. A larger group of samples (n=8 for each 
delivery type per tissue) was tested to confirm our findings.  
 
Detection of immunoreactive IGFBP-1 fragments 
The size of immunoreactive IGFBP-1 and IGFBP-1 fragments was assessed by 
SDS-PAGE and Western immunoblotting. Samples of amniotic fluid, serum or 
placental extracts (2 µl) were mixed with incubation buffer (6 µl) and SDS-PAGE 
sample buffer (2 µl) and run on SDS-PAGE gel as described above. Proteins were 
transferred onto polyvinylidene difluoride (PVDF) membranes. Transfer was 
achieved by the application of 400 mA for 1h at room temperature. After drying, the 
PVDF membranes were incubated with TBS containing 1% BSA for 1h to block any 
subsequent non-specific binding. These membranes were then incubated with 
polyclonal sheep anti-IGFBP-1 antibody at a dilution of 1 in 10 000 for 16h at room 
temperature. After 3 x 15 min washing, the membranes were incubated for a further 
1h with horseradish peroxidase-labelled rabbit anti-sheep IgG (1 in 1000 dilution). 
The immunoreactive proteins were visualised by the addition of TBS containing 
0.03% hydrogen peroxide and 0.05% diaminobenzidene. Colour development was 
stopped by washing with distilled water. 
 
Protease inhibitor studies 
A series of protease inhibitors were used to identify the nature of the IGFBP-1 
proteolytic activity present in amniotic fluid. Ethylene diamine tetraacetic acid (EDTA, 
100 mM), phenyl methyl sulphonyl fluoride (PMSF, 4 mM), aprotinin (10 mg/ml), 
leupeptin (5 mg/ml), pepstatin (3 mg/ml) and Kunitz soybean trypsin inhibitor (STI, 1 
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mg/ml) were used in these studies. Concentrations of this order are reported to be 
effective in the inhibition of breakdown of other IGFBPs [9, 10]. 125I-labelled IGFBP-1 
(2 µl, 30 000 cpm) was incubated with amniotic fluid (2 µl), TBS (2 µl) and protease 
inhibitor at 37 °C for 1h. At the end of this incubation period SDS-PAGE sample 
buffer (2 µl) was added. Samples were applied to a discontinuous SDS-PAGE gel 
under the conditions described above. Gels were then dried and radioactivity 
visualised by exposure to x-ray film.  
 
Digestion of IGFBP-1 by trypsin 
IGFBP-1 purified from amniotic fluid (50 ng) was incubated for 1 hour at 37 °C with 
increasing concentrations of bovine trypsin (Sigma) in the range 0.2-6.4 units/mL in a 
total volume of 7.5 µl. This preparation contained < 0.008 units of chymotrypsin 
activity/mg protein. Samples were then subjected to SDS-PAGE, Western 
immunoblotting and visualisation using diaminobenzidene as described above.  
 
Effect of proteolysis on IGF binding 
Samples of amniotic fluid, which were found to contain immunoreactive IGFBP-1 
fragments were run on SDS-PAGE and transferred onto PVDF membranes as 
described above. Following transfer, membranes were incubated with 125I-IGF-I (30 
000 cpm/ml) for 16h at room temperature. Radioactive IGF-I was visualised by 
autoradiography. 
 
Effect of proteolysis on IGFBP-1 immunoassay 
The effect of protease activity on the IGFBP-1 radioimmunoassay was investigated 
by studying parallelism following sample dilution. Samples of amniotic fluid 
containing intact (n=4) or proteolysed IGFBP-1 (n=4), as identified from Western 
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immunoblotting, were initially diluted 1 in 10 in horse serum and then double diluted 
in horse serum to a final dilution of 1 in 640. Diluted samples were then assayed for 
IGFBP-1 using the radioimmunoassay described previously [23].  
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Results 
Western analysis of amniotic fluid, serum and placental extracts 
Amniotic fluid from elective section deliveries contained IGFBP-1 detectable by 
Western blotting (Figure 1a).  Amniotic fluid obtained from pregnancies in labour or 
with fetal distress showed intact IGFBP-1, as well as smaller immunoreactive 
products of approximately 19 and 12 kDa. Meconium-stained amniotic fluid contained 
little or no immunoreactive IGFBP-1 (Figure 1a).  Maternal and fetal serum (Fig 1b 
and c respectively) and placental extracts (not shown) contained immunoreactive 
IGFBP-1, but no smaller peptides, and the integrity of the IGFBP-1 was not affected 
by the type of delivery.   
 
Proteolysis of 125I-IGFBP-1 by amniotic fluid, serum and tissue extracts 
The same samples used in Figure 1a-c were incubated with 125I-IGFBP-1, and 
analysed by PAGE and autoradiography.  No metabolism of 125I-IGFBP-1 was 
detected in amniotic fluid from elective Caesarean sections (Figure 1d). However, a 
single smaller band of ~12kD was detected in the presence of amniotic fluid from 
pregnancies in labour or with fetal distress but there was no band seen at 19kDa.  All 
the radioactivity in the meconium-stained amniotic fluid was at the dye-front (Figure 
1d), suggesting complete breakdown of the 125I-IGFBP-1. Maternal and fetal serum 
(figure 1 e and f respectively) did not metabolise 125I-IGFBP-1. A further 8 samples of 
each of the 4 types of amniotic fluid (prior to labour, term labour, fetal distress and 
meconium-stained) were analysed for 125I-IGFBP-1 breakdown and for the presence 
of immunoreactive IGFBP-1 fragments. These produced similar results to those 
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described above and indicated that the metabolism of IGFBP-1 varied between 
samples of amniotic fluid.  
We therefore analysed the metabolism of 125I-IGFBP-1 by 146 further samples from 
different pregnancies. No radioactive fragments were observed with amniotic fluid 
taken before labour (Caesarean section) (n=22), while metabolism of 125I-IGFBP-1 
was found in 11/50 (22%) of samples taken during labour, 17/41 (42%) of samples 
from pregnancies with fetal distress, and 27/35 (77%) of meconium-stained samples.  
These differences were statistically significant (p<0.001 by chi2 analysis).   
 
Effect of incubation time on 125I-IGFBP-1 proteolysis 
The proteolysis of 125I-IGFBP-1 in Figure 1(d-f) indicated partial metabolism with 
amniotic fluids from labour or fetal distress pregnancies, but almost complete 
breakdown with meconium-stained fluids.  It was therefore unclear whether the 
nature of the protease responsible was the same similar in these samples, so a more 
detailed time-course was investigated. Figure 2 shows the degradation of 
125I-IGFBP-1 following incubation between 5 minutes and 1 hour with amniotic fluid 
taken from deliveries following labour associated with fetal distress in the presence 
or absence of meconium staining. Following incubation with unstained fluid a faint 
band at 12 kDa was present after 5 minutes incubation (Figure 2a). This became 
more intense as the incubation time increased. There was a reduction of intensity of 
the intact 30 kDa band such that it was barely visible after 60 minutes incubation 
(Figure 2a). Breakdown of 125I-IGFBP-1 was much more rapid in the presence of 
meconium-stained fluid in that after 5 minutes incubation at 37 °C the intact 
125I-IGFBP-1 was no longer visible and a 125I-labelled fragment at approximately 12 
kDa could be clearly seen (Figure 2b). 
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Characterisation of proteolytic activity against IGFBP-1. 
The nature of the protease was characterised by the incubation with protease 
inhibitors.  The metabolism of 125I-IGFBP-1 by meconium-stained or clear amniotic 
fluid was unaffected by EDTA or pepstatin, whereas PMSF, aprotinin, leupeptin and 
STI limited the metabolism of 125I-IGFBP-1 (figure 3). 
  
Trypsin digestion of IGFBP-1 
Incubation of IGFBP-1 purified from amniotic fluid with trypsin resulted in a strikingly 
similar pattern of fragmentation of immunoreactive IGFBP-1 as that described above. 
At trypsin concentrations of 0.8-6.4 units/mL IGFBP-1 proteolysis was evident by the 
dose-dependent appearance of two immunoreactive fragments of approximately 19 
and 12 kDa. A comparison of the effects of trypsin and amniotic fluid on IGFBP-1 is 
shown in Figure 5.  The pattern of immmunoreactive products is very similar, such 
that the main bands are 30kD (intact protein), 19kD and 12kD in both cases. (Figure 
4). 
 
Effect of proteolysis on IGF binding 
IGFBP-1 fragments from amniotic fluid samples in which we had detected proteolytic 
activity and immunoreactive IGFBP-1 fragments (see Figure 1a and 1f) were 
assessed for 125I-IGF-I binding by Western ligand blotting. 125I-IGF-I bound to intact 
IGFBP-1 in these samples but we were not able to detect any binding to lower 
molecular weight IGFBP-1 fragments (Figure 6). 
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Effect of proteolysis on IGFBP-1 RIA 
The effect of proteolysis on the parallelism of dilution in the RIA is shown in Figure 7. 
When the results were adjusted for sample dilution, the IGFBP-1 level in 
non-proteolysed amniotic fluid samples remained constant as the samples were 
diluted. However, proteolysed samples did not dilute in parallel and the apparent 
concentration increased with increasing dilution. 
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Discussion 
In this study we have demonstrated that term amniotic fluid contains proteolytic 
activity directed against IGFBP-1. This proteolytic activity was not confined to 
amniotic fluid samples with obvious meconium staining. Although IGFBP-1 
breakdown was not observed in any samples taken prior to labour onset, it was 
observed in most samples taken after normal labour and labour complicated by fetal 
distress. The rate of 125I-IGFBP-1 breakdown was greater in meconium-stained 
compared to clear amniotic fluid, but the fact that the breakdown fragments were the 
same size and were inhibited in the same way suggests that the same proteolytic 
mechanism may be responsible. 
 
The immunoreactive IGFBP-1 fragment sizes of 12 kDa and 19 kDa suggest that the 
protein is initially cut at a single site. However, the complete loss of immunoreactivity 
in some samples implies further digestion. This is consistent with our radiolabelled 
IGFBP-1 studies where we observed the appearance of a 125I-labelled fragment of 12 
kDa after 5 minutes incubation with amniotic fluid. After 16h incubation, all 
radioactivity was present in very low molecular weight fragments. 
 
Only the intact 125I-IGFBP-1 and the 12 kDa product were seen in our labelled 
IGFBP-1 studies, suggesting that only this fragment was labelled with 125I. 
Examination of the amino acid sequence of IGFBP-1 shows that all of the tyrosines 
available for labelling by 125I are located towards the C-terminal end of the protein 
(Figure 7). Therefore, it seems likely that the smaller 12 kDa fragment seen in our 
labelled IGFBP-1 studies is the C-terminal fragment. 
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Proteolysis of labelled IGFBP-1 was inhibited by PMSF, aprotinin and leupeptin but 
not by pepstatin. This indicates that, like the IGFBP-3 protease in pregnancy [9], the 
enzyme activity responsible for the breakdown of IGFBP-1 in amniotic fluid is a 
serine protease. However, unlike the IGFBP-3 protease, EDTA had no inhibitory 
effect on IGFBP-1 protease activity indicating that the enzyme activity is not 
cation-dependent. 
 
Trypsin and chymotrypsin are likely candidates for the IGFBP-1 proteolysis seen in 
amniotic fluid because not only are they cation-independent, they are also present in 
significant amounts in meconium [25]. Amniotic fluid trypsin levels are particularly 
raised in pathologies associated with fetal compromise. [26, 27]. In addition, the 
finding of markedly reduced amniotic fluid trypsin inhibitor levels after the onset of 
labour [28] is consistent with the increased trypsin-mediated IGFBP-1 proteolysis 
seen in these samples. Furthermore, protease activity was completely inhibited by 
the Kunitz soybean trypsin inhibitor (STI): an inhibitor of trypsin and, to a lesser 
extent, chymotrypsin. However, the most compelling evidence that the IGFBP-1 
proteolysis described results from trypsin activity is the observation that proteolysis of 
IGFBP-1 by a purified trypsin preparation results in immunoreactive fragments of the 
same size as those present in amniotic fluid. 
 
The IGFBPs are composed of highly conserved cysteine-rich C- and N-terminal 
regions with respective sequence homology of 58 and 34% [29]. Structural studies 
have shown that despite differences in the pairing of these cysteines, all form 
disulphide bonds within each of these regions and there are no disulphide linkages 
between the two domains [30]. This structural arrangement suggests that proteolysis 
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of IGFBP-1 within either of these regions is unlikely to result in the fragmentation 
pattern observed here. 
 
The C- and N- terminal regions are separated by a more variable midregion [30, 31] 
with relatively few cysteines (figure 8). Proteolytic cleavage here is more likely to 
result in the pattern observed and is consistent with other IGFBP proteolysis studies 
which show that, to date, all proteolytic cleavage sites of IGFBPs, which have been 
confirmed by sequencing, have been found within the variable midregion of IGFBPs 
[32]. 
 
Trypsin is a highly specific protease that preferentially cleaves proteins on the C-
terminal side of the basic amino acids lysine (k) and arginine (r). There is a 
lycine-rich region within the midregion of the molecule at a point approximately 40% 
from the C-terminal (amino acids 137, 145, 146 and 148) and cleavage here is 
consistent with the fragmentation observed (Figure 9). In addition, previous studies of 
the IGFBP-1 amino acid sequence have demonstrated cleavage site within this 
region following trypsin digestion in vitro [30]. 
The IGFBP-1 proteolysis described here is functionally important because it appears 
to dramatically reduce IGF binding capacity. This is consistent with the functional 
effect of IGFBP-3 proteolysis [11]. Protease activity in amniotic fluid appears to break 
down both labelled and unlabelled IGFBP-1. Under conditions of partial breakdown, 
the 12 and 19 kDa fragments retain some immunoreactivity. However, the proteolytic 
activity clearly has an effect on apparent IGFBP-1 levels determined by 
immunoassay. Thus, although the RIA antibody can recognise IGFBP-1 proteolytic 
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fragments, proteolytic activity has a considerable effect on levels obtained with this 
assay and this makes such measurements unreliable.  
 
Recent studies have indicated the presence of IGFBP-1 proteolytic activity in 
pregnancy by matrix metalloproteases (MMPs) [22]. This activity produced IGFBP-1 
fragments of a similar size to those seen in the present study. However, this is 
unlikely to be the source of the activity we observed in amniotic fluid since this 
activity was not inhibited by EDTA - a known MMP inhibitor. 
 
Finally, the clinical consequences of this activity must be considered. The reduction 
of IGF binding affinity associated with the proteolysis of other IGFBPs is believed to 
be an important means of regulating the tissue availability of IGFs. In the context of 
pregnancy circulating IGFBP-3, protease activity is thought to be a means by which 
the increased IGF availability can alter maternal metabolism to meet the extra 
demands of pregnancy [9, 14]. Although proteolysis was detected only in amniotic 
fluid collected at the very end of pregnancy, it is possible that such activity exists in 
early pregnancy. Such activity may be significant and a useful topic to investigate in 
future studies. Although the function of IGFBP-1 in amniotic fluid is uncertain, the 
presence of high concentrations here suggests that it may be a potent inhibitor of 
IGF action [33]. Modification by proteolysis may significantly affect this activity. In 
addition, elevated second trimester amniotic fluid IGFBP-1 levels have been reported 
in subjects with intrauterine growth restriction at term [34]. Depending on the 
methodology used, this apparent increase may be in part due to the effect of 
proteolytic activity acting on IGFBP-1. 
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Immunometric methods to detect IGFBP-1 in vaginal secretions have been 
developed as a test for premature rupture of membranes [35]. Clearly, this method 
may prove unreliable where IGFBP-1 proteolytic activity is present. Likewise, 
measurement of amniotic fluid IGFBP-1 levels should take account of trypsin-like 
proteolytic activity present in these samples.  
 
Altered concentrations of IGFBP-1 in disorders of pregnancy such as IUGR, pre-
eclampsia, [2, 4, 5] suggest that IGFBP-1 measurement may be a useful marker 
biochemical marker. The finding of IGFBP-1 proteolysis in association with the 
pathology of fetal distress and physiological stress of labour suggest that the 
presence of IGFBP-1 fragments may be of use as a marker of fetal wellbeing. 
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Western immunoblots showing the size distribution of immunoreactive IGFBP-1 present in pregnancy tissues 
(a-c), and autoradiographs showing the size distribution of 125I-IGFBP-1 after overnight incubation at 37ºC 
with the same samples (d-f). Tissues used were amniotic fluid (a,d), maternal sera (b,e) and umbilical cord 
sera (c,f) collected at delivery with clinical conditions indicated. Control lane contained or unlabelled purified 
IGFBP-1 in PBS (a-c) or 125I-IGFBP-1 (d-f)  
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Figure 2  
Breakdown of 125I IGFBP 1 (a d) and endogenous IGFBP 1 (e h) by amniotic fluid from deliveries prior to 
labour onset (a,e), following uncomplicated labour (b,f), labour complicated by fetal distress in the absence 
(c,g) or presence (d,h) of meconium staining. In each blot, the numbers 1-8 represent 8 different samples.  
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Figure 3  
Autoradiograph showing the size distribution of 125I-IGFBP-1 after incubation at 37°C with clear (a) and 
meconium-stained (b) amniotic fluid for the times indicated (minutes). Control sample 125I-IGFBP-1 only 
with no incubation.  
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Figure 4  
Effect of protease inhibitors on 125I-IGFBP-1 proteolysis by clear (a) and meconium stained (b) amniotic 
fluid. Final concentrations of inhibitors were: EDTA 33 mM, PMSF 3.3 mM, leupeptin 1.7 mM, aprotinin 3.3 
mg/ml, STI 3.3 mg/ml, pepstatin 1 mg/ml.  
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Figure 5  
Western immunoblot showing the comparison of IGFBP-1 breakdown following 1 hour incubation at 37°C 
with amniotic fluid and with trypsin at the concentrations indicated (U/ml).  
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Figure 6  
Western ligand blot showing binding of 125I IGF I to IGFBP 1 species present in amniotic fluid collected from 
deliveries as indicated.  
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Effect of IGFBP-1 proteolytic activity on apparent levels of IGFBP-1 determined by RIA after serial dilution. 
IGFBP-1 levels were determined in samples of amniotic fluid with (●) or without (○) evidence of IGFBP-1 
proteolytic activity (n=4 in each group). Because of the large range of absolute levels of IGFBP-1 in these 
samples, IGFBP-1 is expressed as a percentage of the value obtained from the lowest dilution. Dotted line 
denotes expected levels after serial dilution.  
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Proposed mechanism of IGFBP 1 proteolysis by trypsin derived from amniotic fluid. Cysteine rich terminal 
regions, cleavage sites (k) for trypsin within the ‘open’ region and the distribution of tyrosines (y) within the 
protein are indicated.  
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